Royalty Pharma plc (NASDAQ: RPRX) reported Q2 revenue of $555 million, versus $511 million reported last year.

• Increased 2021 guidance: Adjusted Cash Receipts(1) expected to be $2,080 to $2,120 million

For earnings history and earnings-related data on Royalty Pharma plc (RPRX) click here.